UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 2, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At May 5, 2023, 5,645,307,020 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
34
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
53
Item 4.
Controls and Procedures
53
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
53
Item 1A.
Risk Factors
53
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
54
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other InformationN/A
Item 6.
Exhibits
54
Signature
54
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 26, 2023 and February 27, 2022, and for U.S. subsidiaries is as of and for the three months ended April 2, 2023 and April 3, 2022. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2022 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2022 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2022
ACIPAdvisory Committee on Immunization Practices
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
ArenaArena Pharmaceuticals, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Ltd.
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CMAconditional marketing authorisation
Comirnaty*Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine. In the U.S., monovalent mRNA COVID-19 vaccines are no longer emergency use authorized or CDC-recommended, although Comirnaty remains a licensed vaccine.
Cond. J-NDAConditional Japan New Drug Application
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, South Korea, Canada, Australia and New Zealand
Developed Rest of WorldIncludes the following markets: Japan, South Korea, Canada, Australia and New Zealand
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey
EPSearnings per share
ESGEnvironmental, Social and Governance
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FFDCAU.S. Federal Food, Drug and Cosmetic Act
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended April 2, 2023
GAAPGenerally Accepted Accounting Principles
GBTGlobal Blood Therapeutics, Inc.
GPDGlobal Product Development organization
GSKGSK plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JAKJanus kinase
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LOEloss of exclusivity
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
MeridianMeridian Medical Technologies, Inc.
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
MyovantMyovant Sciences Ltd.
NDANew Drug Application
NimbusNimbus Therapeutics, LLC
nmCRPCnon-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
ODToral disintegrating tablet
OnoOno Pharmaceutical Co., Ltd.
OPKOOPKO Health, Inc.
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia Corporation
Prevnar familyIncludes Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult)
PsApsoriatic arthritis
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
SeagenSeagen Inc.
SECU.S. Securities and Exchange Commission
SI&Aselling, informational and administrative
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
WRDMWorldwide Research, Development and Medical
*Paxlovid and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for progression to severe COVID-19, including hospitalization or death. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent has been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)April 2,
2023April 3,
2022
Revenues$18,282 $25,661
Costs and expenses:
Cost of sales(a)
4,886 9,984
Selling, informational and administrative expenses(a)
3,418 2,593
Research and development expenses(a)
2,505 2,301
Acquired in-process research and development expenses21 355
Amortization of intangible assets1,103 835
Restructuring charges and certain acquisition-related costs9 192
Other (income)/deductions net70 350
Income from continuing operations before provision/(benefit) for taxes on income6,270 9,050
Provision/(benefit) for taxes on income715 1,172
Income from continuing operations5,555 7,879
Discontinued operations net of tax1 (9)
Net income before allocation to noncontrolling interests5,556 7,870
Less: Net income attributable to noncontrolling interests13 6
Net income attributable to Pfizer Inc. common shareholders$5,543 $7,864
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.98 $1.40
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders$0.98 $1.40
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.97 $1.37
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders$0.97 $1.37
Weighted-average shares basic5,634 5,617
Weighted-average shares diluted5,727 5,758
(a)Exclusive of amortization of intangible assets.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Net income before allocation to noncontrolling interests$5,556 $7,870
Foreign currency translation adjustments, net101 (363)
Unrealized holding gains/(losses) on derivative financial instruments, net2 203
Reclassification adjustments for (gains)/losses included in net income(a)
303 (213)
305 (10)
Unrealized holding gains/(losses) on available-for-sale securities, net87 (133)
Reclassification adjustments for (gains)/losses included in net income(b)
(509)233
(422)99
Reclassification adjustments related to amortization of prior service costs and other, net(30)(36)
Reclassification adjustments related to curtailments of prior service costs and other, net(5)(11)
(35)(47)
Other comprehensive income/(loss), before tax(50)(321)
Tax provision/(benefit) on other comprehensive income/(loss)(63)(60)
Other comprehensive income/(loss) before allocation to noncontrolling interests$12 $(260)
Comprehensive income/(loss) before allocation to noncontrolling interests$5,569 $7,610
Less: Comprehensive income/(loss) attributable to noncontrolling interests10 6
Comprehensive income/(loss) attributable to Pfizer Inc.$5,558 $7,604
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)April 2,
2023December 31, 2022
(Unaudited)
Assets
Cash and cash equivalents$2,166 $416
Short-term investments17,806 22,316
Trade accounts receivable, less allowance for doubtful accounts: 2023 $465; 2022 $449
12,305 10,952
Inventories9,541 8,981
Current tax assets3,140 3,577
Other current assets5,120 5,017
Total current assets50,078 51,259
Equity-method investments11,175 11,033
Long-term investments3,568 4,036
Property, plant and equipment, less accumulated depreciation: 2023 $15,514; 2022 $15,174
17,052 16,274
Identifiable intangible assets42,002 43,370
Goodwill51,476 51,375
Noncurrent deferred tax assets and other noncurrent tax assets7,302 6,693
Other noncurrent assets12,965 13,163
Total assets$195,617 $197,205
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2023 $3,567; 2022 $2,560
$4,188 $2,945
Trade accounts payable6,123 6,809
Dividends payable 2,303
Income taxes payable1,969 1,587
Accrued compensation and related items2,277 3,407
Deferred revenues1,750 2,520
Other current liabilities20,255 22,568
Total current liabilities36,562 42,138
Long-term debt31,704 32,884
Pension and postretirement benefit obligations2,179 2,250
Noncurrent deferred tax liabilities1,067 1,023
Other taxes payable9,860 9,812
Other noncurrent liabilities13,009 13,180
Total liabilities94,381 101,288
Commitments and Contingencies
Common stock478 476
Additional paid-in capital92,153 91,802
Treasury stock(114,473)(113,969)
Retained earnings131,102 125,656
Accumulated other comprehensive loss(8,289)(8,304)
Total Pfizer Inc. shareholders equity100,970 95,661
Equity attributable to noncontrolling interests266 256
Total equity101,236 95,916
Total liabilities and equity$195,617 $197,205
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 2023
9,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916
Net income5,543 5,543 13 5,556
Other comprehensive income/(loss), net of tax15 15 (3)12
Cash dividends declared, per share: $
Common stock
Share-based payment transactions41 2 350 (12)(504)(97)(249)(249)
Other
Balance, April 2, 2023
9,560 $478 $92,153 (3,915)$(114,473)$131,102 $(8,289)$100,970 $266 $101,236
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 2022
9,471 $473 $90,591 (3,851)$(111,361)$103,394 $(5,897)$77,201 $262 $77,462
Net income7,864 7,864 6 7,870
Other comprehensive income/(loss), net of tax(260)(260) (260)
Cash dividends declared, per share: $
Common stock
Share-based payment transactions23 2 249 (12)(570)(65)(383)(383)
Purchases of common stock(39)(2,000)(2,000)(2,000)
Other3 3 (7)(4)
Balance, April 3, 20229,494 $476 $90,844 (3,903)$(113,931)$111,193 $(6,157)$82,424 $261 $82,685
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Operating Activities
Net income before allocation to noncontrolling interests$5,556 $7,870
Discontinued operations net of tax1 (9)
Net income from continuing operations before allocation to noncontrolling interests5,555 7,879
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization1,487 1,187
Asset write-offs and impairments270 31
Deferred taxes(598)(2,321)
Share-based compensation expense105 86
Benefit plan contributions in excess of expense/income(200)(404)
Other adjustments, net99 815
Other changes in assets and liabilities, net of acquisitions and divestitures(5,507)(730)
Net cash provided by operating activities1,212 6,541
Investing Activities
Purchases of property, plant and equipment(1,139)(643)
Purchases of short-term investments(6,665)(8,758)
Proceeds from redemptions/sales of short-term investments6,400 13,421
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less4,665 3,409
Purchases of long-term investments(51)(676)
Proceeds from redemptions/sales of long-term investments124 52
Acquisition of business, net of cash acquired (6,225)
Other investing activities, net(18)(13)
Net cash provided by/(used in) investing activities3,315 567
Financing Activities
Proceeds from short-term borrowings11
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
226 (220)
Payments on long-term debt(269)(1,609)
Purchases of common stock (2,000)
Cash dividends paid(2,303)(2,249)
Other financing activities, net(436)(501)
Net cash provided by/(used in) financing activities(2,771)(6,578)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(2)(1)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents1,754 529
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period468 1,983
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$2,222 $2,513
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
$329 $354
Interest paid
419 453
Interest rate hedges60 26
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2022 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 26, 2023 and February 27, 2022, and for U.S. subsidiaries is as of and for the three months ended April 2, 2023 and April 3, 2022.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See Note 13A below and Note 17A in our 2022 Form 10-K.
Business development activities impacted financial results in the periods presented. See Notes 2A and 2B below as well as Notes 1A and 2 in our 2022 Form 10-K.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for segment reporting.
B. New Accounting Standard Adopted in 2023
On January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements. See Note 8C.
C. Revenues and Trade Accounts Receivable
Customers Our prescription biopharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies and distributors. In the U.S., we primarily sell our vaccines directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)April 2,
2023December 31, 2022
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,068 $1,200
Other current liabilities:
Accrued rebates4,743 4,479
Other accruals521 430
Other noncurrent liabilities
324 612
Total accrued rebates and other sales-related accruals$6,656 $6,722
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three months ended April 2, 2023 and April 3, 2022, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2022 Form 10-K.
Note 2. Acquisitions, Discontinued Operations and Equity-Method Investment
A. Acquisitions
GBT On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In connection with this business combination, we provisionally recorded: (i) $4.4 billion in Identifiable intangible assets, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1 billion of Goodwill, (iii) $672 million of inventories to be sold over approximately three years, (iv) $568 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Biohaven On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer s previous investment in Biohaven on the acquisition date of approximately $300 million. In connection with this business combination, we provisionally recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&D, (ii) $817 million of inventories to be sold over approximately two years, (iii) $797 million of Goodwill, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $566 million of net deferred tax liabilities and (vii) $476 million of Other current liabilities. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Arena On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in the first quarter of 2023. In connection with this business combination, we recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $490 million of net deferred tax liabilities.
B. Discontinued Operations
Discontinued operations net of tax in the periods presented are post-close adjustments related to the previously disposed discontinued Meridian subsidiary and the Upjohn Business. In the three months ended April 2, 2023 and April 3, 2022, amounts recorded under interim agreements, including TSAs and MSAs, associated with these disposals were not material. Under agreements related to the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, net amounts due from Viatris were approximately $57 million as of April 2, 2023 and net amounts due to Viatris were $94 million as of December 31, 2022. The cash flows associated with the agreements are included in Net cash provided by operating activities. For information about the nature of these agreements, see Note 2B in our 2022 Form 10-K.
C. Equity-Method Investment
Haleon/Consumer Healthcare JV On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of the ordinary shares of Haleon after the demerger.
The carrying value of our investment in Haleon as of April 2, 2023 and as of December 31, 2022 is $11.0 billion and $10.8 billion, respectively, and is reported in Equity-method investments. The fair value of our investment in Haleon as of April 2, 2023, based on quoted market prices of Haleon stock, was $11.8 billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The increase in the value of our investment from December 31, 2022 is primarily due to $90 million in
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
pre-tax foreign currency translation adjustments (see Note 6) and our share of Haleon s earnings. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions net. Our total share of Haleon s earnings generated in the fourth quarter of 2022, which we recorded in our operating results in the first quarter of 2023, was $68 million. Our total share of the JV s earnings generated in the fourth quarter of 2021, which we recorded in our operating results in the first quarter of 2022, was $185 million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of Haleon/the Consumer Healthcare JV was not material to our results of operations in the periods presented. See Note 4.
Summarized financial information for our equity-method investee, Haleon/the Consumer Healthcare JV, for the three months ending December 31, 2022, the most recent period available, and for the three months ending December 31, 2021, is as follows:
Three Months Ended
(MILLIONS)December 31, 2022December 31, 2021
Net sales$3,261 $3,420
Cost of sales(1,496)(1,312)
Gross profit$1,766 $2,108
Income from continuing operations225 590
Net income225 590
Income attributable to shareholders211 578
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Transforming to a More Focused Company Program
In 2019, we announced that we would be incurring costs associated with our Transforming to a More Focused Company Program, a multi-year effort to ensure our cost base aligns appropriately with our operating structure following Pfizer s transformation into a more focused, innovative science-based global biopharmaceutical business. This program includes activities to (i) restructure our corporate enabling functions to appropriately support our operating structure; (ii) transform our commercial go-to-market model; and (iii) optimize our manufacturing network and R&D operations.
The activities associated with transforming our commercial go-to-market model are substantially complete. Activities associated with restructuring our corporate enabling functions and optimizing our manufacturing network and R&D operations are ongoing and are expected to be substantially completed by the end of 2023. The costs to restructure our corporate enabling functions, and to optimize our R&D operations and reduce cycle times, as well as to further prioritize our internal R&D portfolio, primarily include severance and implementation costs. The costs to optimize our manufacturing network largely include severance, implementation costs, product transfer costs, site exit costs, and accelerated depreciation.
From the start of this program in the fourth quarter of 2019 through April 2, 2023, we incurred costs of $3.5 billion, of which $1.4 billion ($1.1 billion of restructuring charges) is associated with Biopharma. We have incurred approximately 85% of total expected costs to date, and we expect the remaining costs to be substantially incurred through 2023.
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Restructuring charges/(credits):
Employee terminations$(36)$25
Asset impairments(10)8
Exit costs/(credits)2 11
Restructuring charges/(credits)(a)
(44)43
Transaction costs(b)
Integration costs and other(c)
52 142
Restructuring charges and certain acquisition-related costs9 192
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
(5)(6)
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales(d)
18 9
Implementation costs recorded in our condensed consolidated statements of income as follows(e):
Cost of sales15 12
Selling, informational and administrative expenses59 74
Research and development expenses11
Total implementation costs85 85
Total costs associated with acquisitions and cost-reduction/productivity initiatives$107 $280
(a)Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: credits of $28 million for the three months ended April 2, 2023 and credits of $4 million for the three months ended April 3, 2022.
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2022(a)
$1,196 $ $8 $1,204
Provision/(credit)(36)(10)2 (44)
Utilization and other(b)
(420)10 (1)(411)
Balance, April 2, 2023(c)
$740 $ $9 $750
(a)Included in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).
(b)Includes adjustments for foreign currency translation.
(c)Included in Other current liabilities ($548 million) and Other noncurrent liabilities ($202 million).
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Interest income$(177)$(14)
Interest expense318 322
Net interest expense141 308
Royalty-related income(204)(173)
Net (gains)/losses on asset disposals(7)(1)
Net (gains)/losses recognized during the period on equity securities(a)
451 699
Income from collaborations, out-licensing arrangements and sales of compound/product rights(68)(9)
Net periodic benefit costs/(credits) other than service costs(80)(283)
Certain legal matters, net(b)
36 79
Certain asset impairments(c)
264
Haleon/Consumer Healthcare JV equity method (income)/loss(d)
(68)(184)
Other, net(e)
(396)(88)
Other (income)/deductions net$70 $350
(a)The losses in the first quarter of 2023 include, among other things, unrealized losses of $363 million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech. The losses in the first quarter of 2022 included, among other things, unrealized losses of $473 million related to our investment in BioNTech.
(b)The first quarter of 2023 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The first quarter of 2022 includes certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.
(c)The first quarter of 2023 primarily represents intangible asset impairment charges, including $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflects unfavorable pivotal trial results and updated commercial forecasts, and $120 million associated with our Biopharma segment due to the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer, acquired in our Array BioPharma Inc. acquisition.
(d)See Note 2C.
(e)The first quarter of 2023 primarily includes, among other things, dividend income of $211 million from our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $92 million from our investment in ViiV.
Additional information about the intangible assets that were impaired during 2023 follows:
Three Months Ended
Fair Value(a)
April 2, 2023
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
Intangible assets Licensing agreements and other(b)
$ $ $ $ $120
Intangible assets IPR&D(b)
94
Intangible assets Developed technology rights(b)
34
Total$ $ $ $ $248
(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2022 Form 10-K.
(b)Reflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 11.4% for the first quarter of 2023, compared to 12.9% for the first quarter of 2022. The lower effective tax rate for the first quarter of 2023, was due to a favorable change in the jurisdictional mix of earnings.
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fifth annual installment of this liability was paid by its April 18, 2023 due date and is reported in current Income taxes payable and the remaining liability is reported in noncurrent Other taxes payable as of April 2, 2023. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2023 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.
See Note 5D in our 2022 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Foreign currency translation adjustments, net(a)
$(25)$(72)
Unrealized holding gains/(losses) on derivative financial instruments, net3 32
Reclassification adjustments for (gains)/losses included in net income21 (22)
24 10
Unrealized holding gains/(losses) on available-for-sale securities, net11 (17)
Reclassification adjustments for (gains)/losses included in net income(64)29
(53)12
Reclassification adjustments related to amortization of prior service costs and other, net(7)(9)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)(2)
(9)(11)
Tax provision/(benefit) on other comprehensive income/(loss)$(63)$(60)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, December 31, 2022
$(8,360)$(412)$220 $248 $(8,304)
Other comprehensive income/(loss)(b)
129 281 (369)(27)15
Balance, April 2, 2023$(8,231)$(131)$(149)$222 $(8,289)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains related to our equity-method investment in Haleon (see Note 2C) and the impact of our net investment hedging program.
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
April 2, 2023December 31, 2022
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair values:
Money market funds$1,165 $ $1,165 $1,588 $ $1,588
Available-for-sale debt securities:
Government and agency non-U.S.
13,278 13,278 15,915 15,915
Government and agency U.S.
927 927 1,313 1,313
Corporate and other
1,914 1,914 1,514 1,514
16,118 16,118 18,743 18,743
Total short-term investments17,283 17,283 20,331 20,331
Other current assets
Derivative assets:
Foreign exchange contracts
734 734 714 714
Total other current assets734 734 714 714
Long-term investments
Equity securities with readily determinable fair values(a)
2,355 2,348 7 2,836 2,823 13
Available-for-sale debt securities:
Government and agency non-U.S.
261 261 280 280
Corporate and other
72 72 72 72
333 333 352 352
Total long-term investments2,688 2,348 340 3,188 2,823 365
Other noncurrent assets
Derivative assets:
Foreign exchange contracts
295 295 364 364
Total derivative assets295 295 364 364
Insurance contracts(b)
700 700 665 665
Total other noncurrent assets995 995 1,028 1,028
Total assets$21,699 $2,348 $19,352 $25,261 $2,823 $22,439
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$ $ $ $10 $ $10
Foreign exchange contracts
382 382 694 694
Total other current liabilities383 383 704 704
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts274 274 321 321
Foreign exchange contracts
832 832 864 864
Total other noncurrent liabilities1,105 1,105 1,185 1,185
Total liabilities$1,488 $ $1,488 $1,889 $ $1,889
(a)Long-term equity securities of $115 million as of April 2, 2023 and $143 million as of December 31, 2022 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion was $32 billion as of April 2, 2023 and $33 billion as of December 31, 2022. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $30 billion as of April 2, 2023 and $30 billion as of December 31, 2022.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
as of April 2, 2023 and December 31, 2022. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
(MILLIONS)April 2,
2023 December 31, 2022
Short-term investments
Equity securities with readily determinable fair values(a)
$1,165 $1,588
Available-for-sale debt securities16,118 18,743
Held-to-maturity debt securities523 1,985
Total Short-term investments$17,806 $22,316
Long-term investments
Equity securities with readily determinable fair values(b)
$2,355 $2,836
Available-for-sale debt securities333 352
Held-to-maturity debt securities52 48
Private equity securities at cost(b)
828 800
Total Long-term investments$3,568 $4,036
Equity-method investments11,175 11,033
Total long-term investments and equity-method investments$14,743 $15,069
Held-to-maturity cash equivalents$436 $679
(a)Includes money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
April 2, 2023December 31, 2022
Gross UnrealizedContractual or Estimated Maturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$13,702 $51 $(214)$13,539 $13,278 $261 $ $15,946 $297 $(48)$16,195
Government and agency U.S.
927 927 927 1,313 1,313
Corporate and other1,992 (7)1,985 1,914 72 1,584 7 (4)1,586
Held-to-maturity debt securities
Time deposits and other
936 936 888 34 14 1,171 1,171
Government and agency non-U.S.
75 75 71 3 1 1,542 1,542
Total debt securities$17,632 $51 $(221)$17,462 $17,077 $371 $15 $21,556 $304 $(53)$21,807
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022
Net (gains)/losses recognized during the period on equity securities(a)
$451 $699
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(33)(11)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$485 $710
(a)Reported in Other (income)/deductions net. See Note 4.
17
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 2, 2023, there were cumulative impairments and downward adjustments of $171 million and upward adjustments of $203 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2023 and 2022.
C. Short-Term Borrowings
Short-term borrowings include:
(MILLIONS)April 2,
2023 December 31, 2022
Current portion of long-term debt, principal amount$3,550 $2,550
Other short-term borrowings, principal amount(a)
622 385
Total short-term borrowings, principal amount
4,172 2,935
Net fair value adjustments17 10
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$4,188 $2,945
(a)Primarily includes cash collateral. See Note 7F.
D. Long-Term Debt
The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:
(MILLIONS)April 2,
2023 December 31, 2022
Total long-term debt, principal amount$30,909 $32,080
Net fair value adjustments related to hedging and purchase accounting966 959
Net unamortized discounts, premiums and debt issuance costs(171)(175)
Other long-term debt 20
Total long-term debt, carried at historical proceeds, as adjusted$31,704 $32,884
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Chinese renminbi, Canadian dollar and Singapore dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.
Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
18
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following summarizes the fair value of the derivative financial instruments and notional amounts:
April 2, 2023December 31, 2022
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$26,179 $809 $1,038 $26,603 $838 $1,196
Interest rate contracts2,250 274 2,250 331
809 1,311 838 1,527
Derivatives not designated as hedging instruments:
Foreign exchange contracts$21,870 220 177 $29,814 240 362
Total$1,029 $1,488 $1,078 $1,889
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5 billion as of April 2, 2023 and $4.4 billion as of December 31, 2022.
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
Gains/(Losses)
Recognized in OID(a)
Gains/(Losses)
Recognized in OCI(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS(a)
Three Months Ended
(MILLIONS)April 2,
2023April 3,
2022April 2,
2023April 3,
2022April 2,
2023April 3,
2022
Derivative Financial Instruments in Cash Flow Hedge Relationships:
Foreign exchange contracts(b)
$ $ $(53)$187 $(356)$195
Amount excluded from effectiveness testing and amortized into earnings(c)
55 16 53 18
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts
48 (156)
Hedged item
(48)156
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign exchange contracts
(213)259
Amount excluded from effectiveness testing and amortized into earnings(c)
67 (74)34 30
Non-Derivative Financial Instruments in Net Investment Hedge Relationships:(d)
Foreign currency short-term borrowings 26
Foreign currency long-term debt (16)23
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts
17 (19)
$17 $(19)$(160)$436 $(269)$243
(a)OID = Other (income)/deductions net, included in Other (income)/deductions net in the condensed consolidated statements of income. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income.
(b)The amounts reclassified from OCI into COS were a net gain of $91 million in the first quarter of 2023 and a net gain of $34 million in the first quarter of 2022. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $235 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 20 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related long-term debt carrying values as of April 2, 2023 and December 31, 2022 were $811 million and $795 million, respectively.